{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T05:08:31Z","timestamp":1667538511226},"reference-count":33,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The emergence of coronavirus SARS-CoV-2, and the subsequent global\nepidemic of COVID-19, brought with it innumerable new clinical experiences across all medical\nspecialties, and psychiatry is no exception. Individuals with serious mental illness, in particular\nschizophrenia and related disorders, may be especially susceptible to coronavirus infection given\nthe overlapping risk factors of vulnerable sociodemographic status, increased challenges with quarantining\nrequirements, and limited compliance with \u201crespiratory etiquette.\u201d The case presented\nhere describes a patient with schizophrenia who was being managed on clozapine and who developed\nsymptomatic COVID-19 infection. Special care was taken to ensure that potential interactions\nbetween clozapine and the associated COVID-19 treatments were safe for the patient\u2019s mental and\nphysical wellbeing.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case Presentation:<\/jats:title>\n<jats:p>A 71-year-old schizophrenic Caucasian male is being managed with clozapine.\nWhile hospitalized, the patient was screened positive for COVID-19 and was admitted to the ICU\ndue to his declining respiratory status. He was treated with both remdesivir and prednisone. He was\nable to fully recover from his COVID-19 infection.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The authors review the clinical characteristics of the case, highlighting both the overlapping\nsynergistic effects and antagonistic influences of clozapine therapy in combination with\nCOVID-19 and its associated treatments. A review of the literature offers an opportunity to examine\nvarious frameworks for individualized clinical decision-making while making the case for\ngreater epidemiologic research into the optimal management of individuals with a psychotic disorder\nwho are diagnosed with COVID-19 infection.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886316666211130142624","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T04:56:54Z","timestamp":1638334614000},"page":"382-386","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clozapine and COVID-19: A Case Report and Clinical Considerations"],"prefix":"10.2174","volume":"17","author":[{"given":"Adam J.","family":"Fusick","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurosciences, University of South Florida Morsani College of Medicine,\nTampa, Florida, USA"},{"name":"Mental Health and Behavioral Sciences Service, James A. Haley Veterans Hospital, Tampa,\nFlorida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dylan","family":"Lahiff","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurosciences, University of South Florida Morsani College of Medicine,\nTampa, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Chatham","sequence":"additional","affiliation":[{"name":"Mental Health and Behavioral Sciences Service, James A. Haley Veterans Hospital, Tampa,\nFlorida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurosciences, University of South Florida Morsani College of Medicine,\nTampa, Florida, USA"},{"name":"Mental Health and Behavioral Sciences Service, James A. Haley Veterans Hospital, Tampa,\nFlorida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12575-020-00128-2","volume":"22","author":"Esakandari H.","year":"2020","unstructured":"Esakandari H.; Nabi-Afjadi M.; Fakkari-Afjadi J.; Farahmandian N.; Miresmaeili S-M.; Bahreini E.; A comprehensive review of COVID-19 characteristics. Biol Proced Online 2020,22(1),19","journal-title":"Biol Proced Online"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1590\/s1678-9946202062044","volume":"62","author":"Oliveira B.A.","year":"2020","unstructured":"Oliveira B.A.; Oliveira L.C.; Sabino E.C.; Okay T.S.; SARS-CoV-2 and the COVID-19 disease: A mini review on diagnostic methods. Rev Inst Med Trop S&#xE3;o Paulo 2020,62,e44","journal-title":"Rev Inst Med Trop S&#xE3;o Paulo"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"102433","DOI":"10.1016\/j.jaut.2020.102433","volume":"109","author":"Rothan H.A.","year":"2020","unstructured":"Rothan H.A.; Byrareddy S.N.; The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020,109,102433","journal-title":"J Autoimmun"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1093\/schbul\/sbaa051","volume":"46","author":"Kozloff N.","year":"2020","unstructured":"Kozloff N.; Mulsant B.H.; Stergiopoulos V.; Voineskos A.N.; The COVID-19 global pandemic: Implications for people with schizophrenia and related disorders. Schizophr Bull 2020,46(4),752-757","journal-title":"Schizophr Bull"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1590\/1516-4446-2020-0010","volume":"42","author":"Fonseca L.","year":"2020","unstructured":"Fonseca L.; Diniz E.; Mendon&#xE7;a G.; Malinowski F.; Mari J.; Gadelha A.; Schizophrenia and COVID-19: Risks and recommendations. Braz J Psychaitry 2020,42(3),236-238","journal-title":"Braz J Psychaitry"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/thoraxjnl-2012-202480","volume":"68","author":"Seminog O.O.","year":"2013","unstructured":"Seminog O.O.; Goldacre M.J.; Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies. Thorax 2013,68(2),171-176","journal-title":"Thorax"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1177\/070674370304800512","volume":"48","author":"Subramaniam M.","year":"2003","unstructured":"Subramaniam M.; Chong S.A.; Pek E.; Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003,48(5),345-347","journal-title":"Can J Psychiatry"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/npr2.12034","volume":"38","author":"Haga T.","year":"2018","unstructured":"Haga T.; Ito K.; Sakashita K.; Iguchi M.; Ono M.; Tatsumi K.; Risk factors for pneumonia in patients with schizophrenia. Neuropsychopharmacol Rep 2018,38(4),204-209","journal-title":"Neuropsychopharmacol Rep"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1177\/0269881118795333","volume":"32","author":"Dzahini O.","year":"2018","unstructured":"Dzahini O.; Singh N.; Taylor D.; Haddad P.M.; Antipsychotic drug use and pneumonia: Systematic review and meta-analysis. J Psychopharmacol 2018,32(11),1167-1181","journal-title":"J Psychopharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/157488611797579230","volume":"6","author":"Raja M.","year":"2011","unstructured":"Raja M.; Clozapine safety, 35 years later. Curr Drug Saf 2011,6(3),164-184","journal-title":"Curr Drug Saf"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2174\/1574886309666140428115040","volume":"9","author":"Raja M.","year":"2014","unstructured":"Raja M.; Raja S.; Clozapine safety, 40 years later. Curr Drug Saf 2014,9(3),163-195","journal-title":"Curr Drug Saf"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1192\/bjb.2020.66","volume":"44","author":"Silva E.","year":"2020","unstructured":"Silva E.; Gee S.; Smith S.; Gaughran F.; Clozapine and COVID-19. BJPsych Bull 2020,44(4),179-180","journal-title":"BJPsych Bull"},{"key":"ref=13","first-page":"1","volume":"214","author":"Ponsford M.","year":"2018","unstructured":"Ponsford M.; Castle D.; Tahir T.; Robinson R.; Wade W.; Steven R.; Bramhall K.; Moody M.; Carne E.; Ford C.; Farewell D.; Williams P.; El-Shanawany T.; Jolles S.; Clozapine is associated with secondary antibody deficiency. Br J Psychiatry 2018,214(2),1-7","journal-title":"Br J Psychiatry"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"200061","DOI":"10.1503\/jpn.200061","volume":"45","author":"Siskind D.","year":"2020","unstructured":"Siskind D.; Honer W.G.; Clark S.; Correll C.U.; Hasan A.; Howes O.; Kane J.M.; Kelly D.L.; Laitman R.; Lee J.; MacCabe J.H.; Myles N.; Nielsen J.; Schulte P.F.; Taylor D.; Verdoux H.; Wheeler A.; Freudenreich O.; Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci 2020,45(4),200061","journal-title":"J Psychiatry Neurosci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/acps.12898","volume":"138","author":"Myles N.","year":"2018","unstructured":"Myles N.; Myles H.; Xia S.; Large M.; Kisely S.; Galletly C.; Bird R.; Siskind D.; Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand 2018,138(2),101-109","journal-title":"Acta Psychiatr Scand"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/wps.20707","volume":"19","author":"de Leon J.","year":"2020","unstructured":"de Leon J.; Sanz E.J.; Nor&#xE9;n G.N.; De Las Cuevas C.; Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics. World Psychiatry 2020,19(1),120-121","journal-title":"World Psychiatry"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1192\/bjp.2020.151","volume":"219","author":"Govind R.","year":"2020","unstructured":"Govind R.; Fonseca de Freitas D.; Pritchard M.; Hayes R.D.; MacCabe J.H.; Clozapine treatment and risk of COVID-19 infection: Retrospective cohort study. Br J Psychiatry 2020,219(1),1-7","journal-title":"Br J Psychiatry"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.schres.2017.03.045","volume":"192","author":"Clark S.R.","year":"2018","unstructured":"Clark S.R.; Warren N.S.; Kim G.; Jankowiak D.; Schubert K.O.; Kisely S.; Forrester T.; Baune B.T.; Siskind D.J.; Elevated clozapine levels associated with infection: A systematic review. Schizophr Res 2018,192,50-56","journal-title":"Schizophr Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.taap.2016.12.003","volume":"316","author":"Regen F.","year":"2017","unstructured":"Regen F.; Herzog I.; Hahn E.; Ruehl C.; Le Bret N.; Dettling M.; Heuser I.; Hellmann-Regen J.; Clozapine-induced agranulocytosis: Evidence for an immune-mediated mechanism from a patient-specific in-vitro approach. Toxicol Appl Pharmacol 2017,316,10-16","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"e100183","DOI":"10.1136\/gpsych-2019-100183","volume":"33","author":"de Leon J.","year":"2020","unstructured":"de Leon J.; Ruan C.J.; Verdoux H.; Wang C.; Clozapine is strongly associated with the risk of pneumonia and inflammation. Gen Psychiatr 2020,33(2),e100183","journal-title":"Gen Psychiatr"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/schbul\/sbaa070","volume":"46","author":"Cranshaw T.","year":"2020","unstructured":"Cranshaw T.; Harikumar T.; COVID-19 infection may cause clozapine intoxication: Case report and discussion. Schizophr Bull 2020,46(4),751","journal-title":"Schizophr Bull"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2045125320959560","DOI":"10.1177\/2045125320959560","volume":"10","author":"Butler M.","year":"2020","unstructured":"Butler M.; Bano F.; Calcia M.; McMullen I.; Sin Fai Lam C.C.; Smith L.J.; Taylor D.; Gee S.; Clozapine prescribing in COVID-19 positive medical inpatients: A case series. Ther Adv Psychopharmacol 2020,10,2045125320959560","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref=23","year":"2019","unstructured":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health COVID-19 Treatment Guidelines PanelAvailable from:(Accessed on: 11\/19\/2020).2019","journal-title":"National Institutes of Health"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.dsx.2020.05.018","volume":"14","author":"Singh A.K.","year":"2020","unstructured":"Singh A.K.; Singh A.; Singh R.; Misra A.; Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr 2020,14(4),641-648","journal-title":"Diabetes Metab Syndr"},{"key":"ref=25","unstructured":"Covid-19 drug interactions University of LiverpoolAvailable from:(Accessed on: 11\/25\/2020)."},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2045125320935306","DOI":"10.1177\/2045125320935306","volume":"10","author":"Bishara D.","year":"2020","unstructured":"Bishara D.; Kalafatis C.; Taylor D.; Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents. Ther Adv Psychopharmacol 2020,10,2045125320935306","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00213-020-05716-4","volume":"238","author":"Plasencia-Garc&#xED;a B.O.","year":"2021","unstructured":"Plasencia-Garc&#xED;a B.O.; Rodr&#xED;guez-Men&#xE9;ndez G.; Rico-Rangel M.I.; Rubio-Garc&#xED;a A.; Torell&#xF3;-Iserte J.; Crespo-Facorro B.; Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review. Psychopharmacology (Berl) 2021,238(2),329-340","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/jama.2020.17023","volume":"324","author":"Sterne J.A.C.","year":"2020","unstructured":"Sterne J.A.C.; Murthy S.; Diaz J.V.; Slutsky A.S.; Villar J.; Angus D.C.; Annane D.; Azevedo L.C.P.; Berwanger O.; Cavalcanti A.B.; Dequin P.F.; Du B.; Emberson J.; Fisher D.; Giraudeau B.; Gordon A.C.; Granholm A.; Green C.; Haynes R.; Heming N.; Higgins J.P.T.; Horby P.; J&#xFC;ni P.; Landray M.J.; Le Gouge A.; Leclerc M.; Lim W.S.; Machado F.R.; McArthur C.; Meziani F.; M&#xF8;ller M.H.; Perner A.; Petersen M.W.; Savovic J.; Tomazini B.; Veiga V.C.; Webb S.; Marshall J.C.; Association between administration of systemic corticosteroids and mortality among critically III patients with Covid-19: A meta-analysis. JAMA WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group2020,324(13),1330-1341","journal-title":"JAMA"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"E756","DOI":"10.1503\/cmaj.200645","volume":"192","author":"Ye Z.","year":"2020","unstructured":"Ye Z.; Wang Y.; Colunga-Lozano L.E.; Prasad M.; Tangamornsuksan W.; Rochwerg B.; Yao L.; Motaghi S.; Couban R.J.; Ghadimi M.; Bala M.M.; Gomaa H.; Fang F.; Xiao Y.; Guyatt G.H.; Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: A systematic review and meta-analysis. CMAJ 2020,192(27),E756-E767","journal-title":"CMAJ"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1440-1819.2011.02260.x","volume":"65","author":"Kenna H.A.","year":"2011","unstructured":"Kenna H.A.; Poon A.W.; de los Angeles C.P.; Koran L.M.; Psychiatric complications of treatment with corticosteroids: Review with case report. Psychiatry Clin Neurosci 2011,65(6),549-560","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/medicines5030082","volume":"5","author":"Manzo C.","year":"2018","unstructured":"Manzo C.; Serra-Mestres J.; Castagna A.; Isetta M.; Behavioral, psychiatric, and cognitive adverse events in older persons treated with glucocorticoids. Medicines (Basel) 2018,5(3),82","journal-title":"Medicines (Basel)"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","volume":"382","author":"Grein J.","year":"2020","unstructured":"Grein J.; Ohmagari N.; Shin D.; Diaz G.; Asperges E.; Castagna A.; Feldt T.; Green G.; Green M.L.; Lescure F.X.; Nicastri E.; Oda R.; Yo K.; Quiros-Roldan E.; Studemeister A.; Redinski J.; Ahmed S.; Bernett J.; Chelliah D.; Chen D.; Chihara S.; Cohen S.H.; Cunningham J.; D\u2019Arminio Monforte A.; Ismail S.; Kato H.; Lapadula G.; L\u2019Her E.; Maeno T.; Majumder S.; Massari M.; Mora-Rillo M.; Mutoh Y.; Nguyen D.; Verweij E.; Zoufaly A.; Osinusi A.O.; DeZure A.; Zhao Y.; Zhong L.; Chokkalingam A.; Elboudwarej E.; Telep L.; Timbs L.; Henne I.; Sellers S.; Cao H.; Tan S.K.; Winterbourne L.; Desai P.; Mera R.; Gaggar A.; Myers R.P.; Brainard D.M.; Childs R.; Flanigan T.; Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020,382(24),2327-2336","journal-title":"N Engl J Med"},{"key":"ref=33","doi-asserted-by":"publisher","DOI":"10.1017\/ipm.2020.67","author":"Gulati G.","year":"2020","unstructured":"Gulati G.; Kelly B.D.; Does remdesivir have any neuropsychiatric adverse effects? Ir J Psychol Med [Online ahead of print]2020","journal-title":"Ir J Psychol Med"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886316666211130142624","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/198428\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886316666211130142624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T09:55:18Z","timestamp":1667469318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/198428\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886316666211130142624","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}